APA (7th ed.) Citation

Vlaar, A. P. J., Lim, E. H. T., deBruin, S., Rückinger, S., Pilz, K., Brouwer, M. C., . . . deBeek, D. v. (2022). The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19. Clinical and Translational Science, 15(4), 854. https://doi.org/10.1111/cts.13213

Chicago Style (17th ed.) Citation

Vlaar, Alexander P. J., et al. "The Anti‐C5a Antibody Vilobelimab Efficiently Inhibits C5a in Patients with Severe COVID‐19." Clinical and Translational Science 15, no. 4 (2022): 854. https://doi.org/10.1111/cts.13213.

MLA (9th ed.) Citation

Vlaar, Alexander P. J., et al. "The Anti‐C5a Antibody Vilobelimab Efficiently Inhibits C5a in Patients with Severe COVID‐19." Clinical and Translational Science, vol. 15, no. 4, 2022, p. 854, https://doi.org/10.1111/cts.13213.